Syndicate Bio to implement new liquid biopsy
offering to advance cancer diagnostics throughout Africa
BOSTON and ROLLE, Switzerland, April 23,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company in the healthcare space and a
leader in data-driven medicine, today announced that Nigeria-based Syndicate Bio has signed on
to implement MSK-ACCESS® powered with SOPHiA DDM™. Syndicate Bio is
the first lab in Africa to adopt
the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first
company to make comprehensive genomic profiling and liquid biopsy
widely available to patients throughout the entire continent. The
implementation of this new technology will further existing work
from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK),
and Syndicate Bio to advance health equity on a global scale.
There are roughly 1 million new cancer patients each year in
Africa and currently,
comprehensive genomic profiling and liquid biopsy testing options
are not widely available. This means that patients are forced to
forego this testing or travel out of continent for these testing
options. Syndicate Bio's implementation of this new offering will
provide cutting-edge liquid biopsy testing to many of these
patients and will help progress the company's goal of advancing
genomics and precision medicine in an area of the world that has
been historically underserved in these areas.
"Partnering with SOPHiA Genetics to bring MSK-ACCESS® powered
with SOPHiA DDM™ to our lab is a monumental step in accelerating
the cancer treatment and research landscape across Africa, beginning in Nigeria. Next-generation sequencing
technologies in oncology and liquid biopsy, which this
collaboration enables, hold the potential for creating a
leapfrogging opportunity in the oncology treatment and research
landscape in Africa," said
Abasi Ene-Obong, PhD., Founder, Syndicate Bio. "Through this
collaboration, we aim to enable the widespread application of
precision medicine in oncology across Africa, and thus contributing to the
improvement of patient outcomes across the African continent. We
believe our scientific expertise, combined with AI-enabled
technologies and data-driven solutions enabled by SOPHiA GENETICS,
presents a unique opportunity to fundamentally transform the
journey of cancer patients through non-invasive cancer analysis,
predictive genetic testing, and effective precision medicine."
Syndicate Bio is driving genomics and precision medicine
initiatives across the world's most diverse regions through
large-scale partnerships with governments, industry, and other
stakeholders. Through its work, Syndicate Bio is making local
impact while accelerating drug discovery and development. By
focusing on Africa, Syndicate Bio
is poised to make a significant impact, starting with Nigeria, by introducing its pioneering
clinical oncology offerings in an underserved region. Through this
endeavor, Syndicate Bio aims to improve cancer diagnosis and
treatment for African patients. This initiative not only
facilitates local next-generation sequencing (NGS) testing and
liquid biopsy testing but also extends access to clinical trial
participation, empowering patients and healthcare providers
alike.
MSK-ACCESS® powered with SOPHiA DDM™ is a
decentralized version of a highly validated ctDNA test
developed by MSK that involves the deep sequencing of 146 key
cancer-associated genes, and will augment Syndicate Bio's tumor
profiling capabilities, allowing them to utilize a small blood
sample to generate a comprehensive report in an efficient and
expedited time frame. The use of liquid biopsy is less invasive
than traditional biopsy, and can help simplify patient
monitoring, whilst driving the uptake of precision medicine. The
offering combines the sophisticated analytics, state-of-the-art
algorithms, and decentralized, cloud-based offerings
of the SOPHiA DDM™ Platform, with the scientific and clinical
expertise of MSK in cancer genomics to provide a best-in-class
liquid biopsy solution.
"In our mission to democratize data-driven medicine, our
decentralized global network and unique set of
partnerships enable us to help reach underserved populations, just
as those that are served by Syndicate Bio," said Philippe Menu,
MD, PhD., Chief Medical Officer, SOPHiA
GENETICS. "By implementing this solution, Syndicate Bio
will make a measurable impact throughout Africa, while also helping to generate an
unparalleled and comprehensive dataset and provide invaluable
insights and knowledge to shape the future of global
healthcare."
In late 2023, SOPHiA GENETICS and MSK announced they are working
in partnership with AstraZeneca to bring the world-class
MSK-ACCESS® powered with SOPHiA DDM™ testing solution to countries
and regions around the globe, including underserved areas where
access to testing remains scarce.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on X, LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to data-driven
medicine by using AI to unlock insights to deliver world-class care
to patients across the globe. It is the creator of SOPHiA DDM™, a
platform that analyzes complex genomic and multimodal data and
generates real-time, actionable insights for a broad global network
of hospital, laboratory, and biopharma institutions. For more
information, visit SOPHiAGENETICS.COM and connect with us on
LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified
otherwise. MSK-ACCESS® powered with SOPHiA DDM™ is a
product in development and may not be available for sale. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
MSK Disclosure:
Memorial Sloan Kettering
Cancer Center (MSK) has institutional financial interests related
to SOPHiA GENETICS.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
About Syndicate Bio
Syndicate Bio is a platform
biotech driving genomics and precision medicine initiatives across
the world's most diverse regions. Syndicate Bio uses large-scale
partnerships with governments, industry, and other stakeholders to
drive local precision medicine impact and accelerate drug discovery
and development.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-syndicate-bio-as-first-liquid-biopsy-customer-in-africa-302124024.html
SOURCE SOPHiA GENETICS